AlperBSMalone-MosesMMcLellanJS, et al.Thrombolysis in acute ischaemic stroke: time for a rethink?BMJ. 2015;350:h1075.
2.
EmbersonJLeesKRLydenP, et al.Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischemic stroke: a meta-analysis of individual patient data from randomized trials. Lancet. 2014;384(9958):1929–1935.
3.
PowersWJRabinsteinAAAckersonT, et al.2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110.
4.
YaghiSEisenbergerAWilleyJZ. Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment. JAMA Neurol. 2014;71(9):1181–1185.
5.
MesséSRKhatriPReevesMJ, et al.Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry. Neurology. 2016;87(15):1565–1574.
6.
KhatriPKleindorferDODevlinT, et al.Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial. JAMA. 2018;320(2):156–166.
7.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587.
8.
YouSSaxenaAWangX, et al.Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis. Stroke Vasc Neurol. 2018;3(1):22–27.
